Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2015		Jun. 30, 2014
Cash flows from operating activities:
Net loss	$ (12,854)		$ (16,697)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Share-based compensation	563		1,361
Change in fair value of contingent consideration liability	(14,032)		(6,449)
Amortization of debt discount, deferred interest and right-to-borrow asset	1,180		1,027
Amortization of premium on available-for-sale securities	80		50
Depreciation and amortization	1,602		1,670
Impairment of property and equipment	1,381		0
Changes in operating assets and liabilities:
Receivables	(130)		(889)
Inventory	2,322		(527)
Prepaid expenses and other current assets	1,544		(626)
Accounts payable	819		(1,134)
Accrued clinical and other accrued liabilities	(2,048)		(830)
Deferred revenues	(1,119)		(1,093)
Other liabilities	(185)		(468)
Net cash used in operating activities	(20,877)		(24,605)
Cash flows from investing activities:
Purchases of available-for-sale securities	(5,796)		(33,130)
Maturities of available-for-sale securities	21,790		8,575
Purchases of property and equipment	(44)		(2,461)
Net cash provided by (used in) investing activities	15,950		(27,016)
Cash flows from financing activities:
Proceeds from issuance of common stock and warrants and exercise of stock options and stock purchase rights	31		198
Change in restricted cash	2,757		(5,562)
Payment on contingent consideration liability	(868)		(251)
Proceeds from financing obligations, net of issuance costs	0		50,830
Payments of financing obligations	0		(383)
Net cash provided by financing activities	1,920		44,832
Net decrease in cash and cash equivalents	(3,007)		(6,789)
Cash and cash equivalents at beginning of period	15,200	[1]	17,306
Cash and cash equivalents at end of period	12,193		10,517
Non cash investing and financing activities:
Value of warrants issued with royalty securitization financing	0		1,721
Value of the beneficial conversion feature related to borrowings against the Teva Note	0		1,032
Value of right-to-borrow asset reclassified as debt discount	$ 0		$ 570

[1] (1) The condensed consolidated balance sheet at December 31, 2014 has been derived from audited consolidated financial statements at that date.